Skip to main content
Matthew Neville on Muck Rack

Matthew Neville

(He/Him)
  • Content Creator, Team Valley Group
Morpeth, Newcastle upon Tyne
As seen in: Nature, medRxiv, Energy Central, Bdaily, Pet News 2Day, Daily Star News Today, The Courier (Newcastle University), Washington Post Today, Bitcoin Isle, Bloomberg News Today and
Correspondent for Bdaily

Get in touch with Matthew

Contact Matthew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Author Correction: Complex de novo structural variants are an underestimated cause of rare disorders - Nature Communications

|
By Hyunchul Jung, Tsun-Po Yang, Susan Walker, Petr Danecek, O. Isaac Garcia-Salinas, Matthew Neville, Joseph Christopher, Isidro Cortes-Ciriano, Helen V Firth, Aylwyn Scally, Matthew E Hurles, Peter Campbell, Raheleh Rahbari
| Nature Verified
Correction to: Nature Communications https://doi.org/10.1038/s41467-025-64722-2, published online 3 November 2025 In the version of this article initially published, there was a typographical error in the second paragraph of the Discussion section, where in the text now reading “In addition, 66 of 145 (46%) pathogenic SVs identified in our study were balanced rearrangements,” 66 of 145 (46%) originally read “51 of 151 (34%).” In Fig.
Open in Who Shared View Duplicates (5) Issue with article?

AI and the legal sector

|
By Matthew Neville
| Net-Defence Verified
Artificial intelligence (AI) is no longer a futuristic concept; it is a present-day reality that is transforming how businesses around the globe operate, particularly in the legal sector. From automating routine tasks to enhancing cyber security measures, AI is changing the way legal professionals work, making processes more efficient, accurate, and secure. However, with innovation comes new challenges.
Open in Who Shared Issue with article?

Sperm sequencing reveals extensive positive selection in the male germline

|
By Matthew Neville, Andrew Lawson, Rashesh Sanghvi, Federico Abascal
| medRxiv
I.M., M.R.S., and P.J.C. are co-founders, shareholders, and consultants for Quotient Therapeutics Ltd. R.E.A. is an employee of Quotient Therapeutics Ltd. M.E.H. is a co-founder of, consultant to and holds shares in Congenica, a genetics diagnostic company. This research is supported by core funding from Wellcome Trust. R.R. is funded by Cancer Research UK (C66259/A27114) and Medical Research Council (MR/W025353/1).
Open in Who Shared Issue with article?
See all 75 licensed articles (5,294 Total)